Reply to the Editor  by Stamou, Sotiris C. & Lobdell, Kevin W.
investment was necessary. The impact
of those strategieswas analyzed bymul-
tivariate logistic regression (unpub-
lished data). Risk-adjusted hospital
mortality declined (from 11.5% to
3.6%, P ¼ .003) after these strategies
were implemented. Survival benefit
was particularly evident in high-risk pa-
tients (Euroscore>7), in which opera-
tions performed prior to the quality
programwere independently associated
with greater mortality (odds ratio¼ 4.8;
95% confidence interval 1.6–17.4; P¼
.005). There was no difference in low-
risk patients (Euroscore<6). Therefore,
multimodal strategies in our center re-
markably improved the outcomes of
high-riskcardiac surgerypatients, asop-
posed to low-risk patients, which are
probably less dependent on the system.
Quality in cardiac surgery is ulti-
mately a surgeon’s responsibility and
should be part of the training of young
surgeons. We would like to congratu-
late Dr Stamou and colleagues on their
excellent work on an extremely impor-
tant subject.
Fernando A. Atik, MD
Instituto de Cardiologia do Distrito
Federal
Fundac¸a˜o Universita´ria de
Cardiologia
Brasilia, Brazil
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Letters to the EditorReply to the Editor:
We appreciate Dr Atik’s kind com-
ments and thoughtful questions. Addi-
tionally, his efforts are to be recognized
and commended. Our quality improve-
ment program (QIP)1,2 was developed
to address opportunities to reduce
mortality and mitigate the risk of254 The Journal of Thoracic andmajormorbidity (nosocomial infections,
acute renal failure, hemorrhage, reop-
erations, etc) through elimination of
variation while reliably applying the
best available evidence as well as best
practices. Regarding the comment
about severity scores, The Society of
Thoracic Surgeons (STS)–National
Cardiac Database allowed us to com-
pare our performance to national aver-
ages and guided our efforts. STS
developed definitions for key data ele-
ments, providing a common language
and standards. STS also developed
risk-adjusted mortality and morbidity
algorithms to provide benchmark mea-
sures that helped in the construction of
our standard operating procedure. STS
risk scores were routinely recorded in
our QIP efforts and used to calculate
expected mortality and compare it
with the national average. However,
reporting risk scores was beyond our
focus. The most important finding of
our article was that by building a QIP,
a measurable and significant decrease
in mortality can be accomplished, and
on that regard, our article was among
the first to report such a finding.
We tend to disagree with Dr Atik’s
comments thatQIPs follow institutional
or regional/national initiatives. A QIP
can follow both national/regional initia-
tives and at the same time be tailored to
each institution’s needs and particulari-
ties. Our QIP was structured based on
STS guidelines and best evidence prac-
tices butwas also adjusted to our institu-
tion’s particular goals.
An important finding of our work is
that a QIP did not improve dramati-
cally the outcomes on diabetic patients,
as previously reported.3 Similarly, Van
Den Berghe and colleagues3 demon-
strated that with their intensive insulin
therapy protocol, they were able to re-
duce mortality of all medical/surgical
intensive care unit patients, except
those with a prior history of diabetes.
Our investigation corroborated this
finding that diabetics are a high-risk
subset of patients on which future
QIP efforts should focus. The presence
of small target vessels (diffuse coro-Cardiovascular Surgery c July 2009nary artery disease) frequently encoun-
tered in diabetic patients, the higher
risk for wound infection, and the
higher risk of mortality compared
with nondiabetic patients as well as
the resistance of diabetic patients to
improve with QIP initiatives provided
the rationale for our proposition.
We tend to agree with Dr Atik’s
statement that ‘‘because processes of
care vary widely among cardiac sur-
gery programs, there are no ‘recipes’
that can be universally applied, due
to system-based particularities.’’
However, common denominators
of successful QIP efforts include
a dedicated multidisciplinary team
with common goals, a systems-based
approach, accurate communication,
adherence to strict protocols, and mon-
itoring compliance. In this respect,
some universally applied rules may ap-
ply. Regarding the reasons for the
change in outcomes, we believe there
is a multifactorial etiology: mainly
the absence of a dedicated multidisci-
plinary team, the lack of a monitoring
tool to measure compliance to the pro-
tocols, and individualized rather than
a team approach to clinical problem
solving during the initial period before
development of QIP. In contradistinc-
tion, our systems-based approach,
standardization, team building, consis-
tent and accurate communication, and
active management of change and
quality accounted for a recent decline
of 48% in mortality.
The financial impact (investment
and savings) of QIP is indeed crucial.
We previously demonstrated that by
implementing QIP, a significant in-
crease in the early extubation rates,
a decrease in intensive care unit stay,
and resource utilization can be accom-
plished.2 We are in the process of ana-
lyzing the specific financial impact of
our QIP, and this will be the focus of
a future publication. We believe that
by using a unique database linking
clinical and financial outcomes
through a focus on quality, cost con-
tainment in cardiac surgical care can
be achieved by identifying and
southern area of Japan, such as Oki-
nawa, and approximately 5% in the
Caribbean region compared with 1%
in Europe and the United States.
There have been several reports of
HTLV-1 transmission in association
with organ transplantation (Table 1).1-4
However, no report describes a trans-
mission of HTLV-1 by lung transplan-
tation. We describe the first case of
HTLV-1 transmission from a seroposi-
tive donor via lung transplantation.
A 38-year-old woman had abnormal
shadows on a chest x-ray at a healthcare
examination. Video-assisted thora-
coscopic surgical lung biopsy was
performed, and usual interstitial pneu-
monia was diagnosed. Despite some
drug treatments, she had dry cough
and dyspnea that gradually worsened.
In 2003, at the age of 42 years, she
was considered eligible for bilateral
living-donor lobar lung transplantation
The patient’s general condition im-
proved after the lung transplantation.
In November 2008, her oxygen sat-
uration was 98% to 99% at room air.
However, serologic follow-up demon-
strated that she had acquired HTLV-I
infection posttransplantation. Antibody
titers were as follows: 256 times after 9
months, more than 8192 times in Au-
gust 2006, 2048 times in April 2008.
Remesar and colleagues1 reported
the first case of HTLV-1 infection
transmitted by organ transplantation
(a child who received a kidney from
her infected mother). The seroconver-
sion was observed 83 days after trans-
plantation. Nakatsuji and colleagues2
described a kidney transplant recipient
who presented with tropical spastic
paraparesis 4 years posttransplanta-
tion. Toro and colleagues3 reported
the transmission of HTLV-1 from
Letters to the Editorreducing costly complications, im-
proving efficiencies of care, and reduc-
ing resource utilization.
Sotiris C. Stamou, MD, PhD
Kevin W. Lobdell, MD
Carolinas Heart and Vascular
Institute
Charlotte, NC
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T-LYMPHOTROPIC VIRUS
TYPE I BY BILATERAL
LIVING-DONOR LOBAR LUNG
TRANSPLANTATION
To the Editor:
Human T-lymphotropic virus type I
(HTLV-I) is an etiologic agent for
adult T-cell leukemia/lymphoma and
HTLV-I–associatedmyelopathy/tropi-
cal spastic paraparesis. Most HTLV-I
infections are attributable to transmis-
sion from mother to child or to sexual
contact later in life, whereas transfu-
sion is perhaps the most efficient
mode of viral transmission. Seropreva-
lence of HTLV-1 among high-risk
populations is 10% to 30% in the
at Okayama University. The patient
was negative for anti-HTLV-I anti-
body. The younger sister was positive
less than 16 times for anti-HTLV-I an-
tibody. Because the patient’s condition
was severe and deteriorating, she was
considered to be in urgent need of lung
transplantation. In addition, there are
no reports of HTLV-I transmission by
lung transplantation. Therefore, lung
transplantation was performed using
lungs from an elder brother and a youn-
ger sister in August 2003. Before the
transplant, the lungs were flushed with
1LofEuro-Collins solution,whichcon-
sists of 115 mmol/L monopotassium,
10 mmol/L sodium, and 3.6% glucose,
both antegradely and retrogradely.5
a single donor to 3 organ (2 kidneys
and 1 liver) transplant recipients, who
subsequently developed tropical spas-
tic paraparesis within 2 years post-
transplant.
Although the lungs were pretreated
with preservative solution, transmission
ofHTLV-1 could not be prevented.Ap-
proximately 5 years posttransplant, our
patient demonstrates neither neurologic
nor hematologic evidence of HTLV-I–
related disease. However, this patient
should be followed up for adult T-cell
leukemia/lymphoma and tropical spas-
tic paraparesis.
Satomi Yara, MD, PhDa
Jiro Fujita, MD, PhDa
Hiroshi Date, MD, PhDb,c
TABLE 1. Review of the literature about transmission of human T-lymphotropic virus type I after solid-organ transplantation
First author Year Age and sex Organ Clinical features References
Remesar 2000 Daughter Kidney None 1
Nakatsuji 2000 50 M Kidney HTLV-1–associated myelopathy 2
Toro 2003 53 F* Kidney Subacute myelopathy 3
Toro 2003 55 My Kidney Subacute myelopathy 3
Toro 2003 44 Fz Liver Subacute myelopathy 3
Zarranz 2003 54 F* Kidney Myelopathy 4
Zarranz 2003 57 My Kidney Myelopathy 4
Zarranz 2003 44 Fz Liver Myelopathy 4
Yara 2008 42 F Lung None Present report
HTLV, Human T-lymphotropic virus type I. *, y, zThe same patients.
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